The focus of the industry on living human beings and highly regulated standards are unique to business leaders. These aspects make the sector an ideal incubator for innovation. They have led to major breakthroughs in biofuels, agricultural yields and life-saving pharmaceuticals.
Biotech startups have a myriad of choices when it comes to revenue generation strategies, with the majority opting for a technology-based partnership or an out-licensing and asset creation strategy. Technology partnering can result in more revenue and lower financial risk, while asset creation and outlicensing strategies can yield greater returns. A growing number of biotechs at the research stage use an hybrid model that blends both approaches.
The people who choose the approach of developing based on products will succeed commercially if they can get their pipeline to the right stage and attract a go to these guys large pharmaceutical partner or an investor with deep pockets. This is costly, however, and balancing opportunistic approaches to leveraging outside resources while making the right scientific decision-making about projects that are homegrown is crucial.
Alternately, the „platform“ model is an alternative path to revenue. It is less expensive than product-oriented research, but is a risky option. In this model biotechs create and own their own platform technology prior to teaming with pharma giants to create a portfolio of drug-discovery projects that target specific diseases (i.e. disease x in biology y). This is the method Advinus Therapeutics and a few others have followed.